Skip to content

Evaluation of the analgesic effect of oxycodone combined with ropivacaine in thoracic paravertebral plane block during the perioperative period of minimally invasive thoracoscopic surgery and its influence on postoperative pulmonary complications

Evaluation of the analgesic effect of oxycodone combined with ropivacaine in thoracic paravertebral plane block during the perioperative period of minimally invasive thoracoscopic surgery and its influence on postoperative pulmonary complications

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106398
Enrollment
Unknown
Registered
2025-07-23
Start date
2024-06-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung tumor

Interventions

The ropivacaine erector spinae plane block group (Group A) :For group A patients, 30 ml of 0.375% ropivacaine was administered immediately after the surgery under ultrasound guidance for spinal muscle
The oxycodone combined with ropivacaine erector spinae plane block group (Group B):For group B patients, 30 ml of a mixture of 5 mg oxycodone and 0.375% ropivacaine was given immediately after the sur

Sponsors

Xuzhou Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Subjects must meet all of the following inclusion criteria to be enrolled in this study: 1. Undergoing minimally invasive thoracoscopic lobectomy, aged 18 years or older; 2. American Society of Anesthesiologists (ASA) classification of grade I or II; 3. Having surgical indications, having signed the informed consent form and willing to accept follow-up.

Exclusion criteria

Exclusion criteria: Any of the following conditions would disqualify a participant from being included in this study: 1. Obese patients with a BMI greater than 30 kg/m2; 2. Patients with obvious cardiac, pulmonary, liver, kidney and brain functional abnormalities before the surgery; 3. Patients with cognitive or mental disorders or those who cannot cooperate; 4. Patients with COPD before the surgery or those with pulmonary infections within one month. 5. Abnormal platelet and coagulation function or electrolyte and acid-base imbalance; 6. Damaged or infected puncture site, BMI greater than 30 kg/m2, etc.; 7. Complicated with neuromuscular system diseases; 8. Long-term use of analgesic drugs or history of drug abuse; 9. Chronic pain diseases; 10. Previous history of heavy drinking; 11. Allergic to opioid drugs, local anesthetic drugs, or having an allergic constitution and not suitable for oxycodone.

Design outcomes

Primary

MeasureTime frame
The VAS score for coughing at 24 hours after the operation;

Secondary

MeasureTime frame
The duration of erector spinae plane block resolution;The VAS scores at rest and during coughing at other time points;The time of the first press of the postoperative analgesic pump;The proportion of patients who pressed the pain relief pump more than 3 times;The cumulative dosage of oxycodone over 48 hours;Pain relief satisfaction score;The incidence of postoperative pulmonary complications;Severity grading and ratio of postoperative pulmonary complications;QoR-40 Recovery Scale;The incidence rate of adverse reactions such as nausea and vomiting within 48 hours after the operation;Complications related to thoracic erector spinae plane block;Postoperative recovery-related indicators;

Countries

China

Contacts

Public ContactWenwen Ma

Xuzhou Cancer Hospital

494247913@qq.com+86 181 1571 5920

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026